NEW: @bancosantander now offers POL trading in Germany to all Openbank customers, expanding to Spain soon.One of Europe’s largest banks is bringing POL to millions, backed by Santander’s guarantees and full MiCA investor protections. A major step for institutional adoption. https://t.co/vmE3VpH6X5 ...

Core Insights - Santander Group's digital banking arm, Openbank, has launched cryptocurrency trading for customers in Germany, with plans to expand to Spain soon [1][2] - The service allows users to buy, sell, and hold five cryptocurrencies: bitcoin (BTC), ether (ETH), litecoin (LTC), polygon (MATIC), and cardano (ADA), alongside traditional investment options [1] - The bank charges a transaction fee of 1.49% with a minimum fee of 1 euro ($1.2), and there are no custody fees involved [3] Group 1 - Openbank enables customers to trade cryptocurrencies without transferring funds to external platforms, consolidating investments under Santander's services [2] - The bank aims to meet customer demand by integrating major cryptocurrencies into its investment platform [2] - Future plans include adding more cryptocurrencies and features like crypto-to-crypto conversions [3] Group 2 - Santander Private Bank has previously allowed clients in Switzerland to trade BTC and ETH, utilizing custody technology from Taurus [4]

转自：新华财经 •桑坦德银行：英国央行或已结束降息，薪资通胀黏性支撑鹰派立场 •标普：预计美联储9月降息25基点至4.00%-4.25% •RBC BlueBay：预测美联储2025年累计降息75基点 •凯投宏观分析师表示，目前市场确实定价美联储会进行多次降息。总体而言，这或许表明，美联储政 策出现鹰派意外的门槛略低于出现鸽派意外的门槛，美联储很可能会坚持其谨慎的沟通方式，不会透露 太多信息。 •德国9月ZEW经济景气指数意外升至37.3（前值34.7），远超市场预期的25，反映投资者对经济复苏持 谨慎乐观；但现状指数恶化，凸显当下疲软。德国ZEW总裁指出，德国9月汽车、化工、制药及金属等 出口行业前景改善是主因，但美国关税与国内"改革秋季"政策不确定性仍构成重大风险。 •中金公司分析指出，2025年9月FOMC会议降息25基点预期概率已超90%（CME FedWatch），10月、12 月再降息概率均超70%。触发因素为美国8月CPI同比2.9%、核心CPI 3.1%，通胀温和；8月非农仅增2.2 万，叠加就业数据大幅下修（累计少报91.1万岗位），劳动力市场明显走弱。 •麦肯锡预测显示，至2030年，全球 ...

Summary of Key Points Core Viewpoint - The document provides information regarding the total number of voting rights and shares for Sanofi, a French société anonyme, as required by French commercial regulations. Group 1: Voting Rights and Shares - As of August 31, 2025, Sanofi has a total of 1,227,469,992 issued shares [1] - The number of real voting rights, excluding treasury shares, is 1,352,853,696 [1] - The theoretical number of voting rights, including treasury shares, is 1,361,794,887 [1] Group 2: Company Information - Sanofi has a registered share capital of €2,454,937,946 [1] - The company is registered at the Paris Commercial and Companies Registry under number 395 030 844 [1] - The registered office is located at 46, avenue de la Grande Armée, 75017 Paris, France [1]

Group 1: European Central Bank and Eurozone Bonds - Santander Bank analysts expect the European Central Bank (ECB) to maintain the deposit rate at 2.00% until later this year, indicating that 2% may be the lower limit for this rate cycle [1] - Barclays reports a significant decrease in net supply of Eurozone government bonds, projecting a shift from a net issuance of 780 billion euros in September to a negative 150 billion euros in October, which may support the bond market [1] Group 2: U.S. Economic Indicators and Federal Reserve Actions - ICIS economists highlight that the U.S. August CPI report complicates the Federal Reserve's interest rate path, with inflation and employment data showing conflicting signals [2] - Market expectations indicate a high probability (90%) that the Federal Reserve will initiate a rate cut of 25 basis points in the upcoming meeting, with a potential for a more aggressive cut if economic conditions worsen [4] Group 3: Japanese Economic Outlook - Moody's economists note that Japan's inflation is primarily cost-push, lacking strong demand-driven inflation, leading the Bank of Japan to likely remain on hold until economic signals become clearer [2] Group 4: Indian Economic Growth - Dun & Bradstreet reports a significant year-on-year GDP growth of 7.8% for India in Q1 FY2026, with strong performance in manufacturing sectors such as basic metals and electrical equipment [3] - The Indian central bank maintains a neutral stance with a repo rate of 5.5%, while liquidity remains in surplus [3]

Core Insights - The FDA has granted fast track designation to Sanofi's SAR402663, a one-time intravitreal gene therapy for neovascular age-related macular degeneration (AMD) [1][7] - The fast track designation aims to expedite the development and review of treatments for serious conditions, addressing unmet medical needs [1] Company Overview - Sanofi is an R&D driven biopharma company focused on improving lives through innovative medicines and vaccines, with a commitment to addressing urgent healthcare challenges [5] - The company is exploring therapies for various neurological diseases, including AMD, and aims to leverage scientific innovation in ophthalmology for growth [4] Product Details - SAR402663 delivers genetic material designed to inhibit vascular endothelial growth factor (VEGF), addressing the underlying pathology of neovascular AMD by reducing abnormal blood vessel growth and minimizing retina damage [2] - The therapy aims to significantly reduce the treatment burden by eliminating the need for frequent intravitreal injections [2] Market Context - Neovascular AMD affects over one million people in the US and approximately six million people worldwide, leading to significant vision loss and impacting quality of life [3][7] - AMD is a progressive degeneration of the retina that affects around 200 million people globally, highlighting the substantial market potential for effective treatments [3]

Sabadell CEO Cesar Gonzalez-Bueno expects BBVA to improve its initial takeover bid for Sabadell Bank, as the current offer undervalues the institution, reported Reuters. His remarks came following BBVA's official initiation of a takeover bid for Sabadell earlier this week. Gonzalez-Bueno remarked at a financial event organised by Barclays in New York, “This offer is most probably not the last one, because everybody agrees that this offer lacks merits.” During the same event BBVA's CEO Onur Genç describe ...

Group 1 - The U.S. Commodity Futures Trading Commission (CFTC) has announced charges against multiple firms for compliance violations, resulting in a total fine of $8.3 million [1] - Citigroup was fined $1.5 million for failing to submit accurate large trader reports from at least 2015 to 2022 and for not maintaining regulatory records for 10 weeks in 2023 [1] - UBS was penalized $5 million for inadequate supervision of its trading monitoring program from at least 2015 to 2024 [1] Group 2 - SMBC Capital Markets, Santander Bank, and Bank of New York Mellon were each fined $500,000 for record-keeping and supervision violations [1] - The CFTC stated that the involved companies have completed or are nearing completion of remedial measures and have agreed to avoid further violations of the Commodity Exchange Act and CFTC regulations [1]

Core Insights - Amlitelimab, a monoclonal antibody targeting OX40-ligand, met all primary and key secondary endpoints in the COAST 1 phase 3 study for atopic dermatitis, showing significant skin clearance and reduced disease severity compared to placebo at Week 24 [1][2][5] - The study demonstrated that amlitelimab can be administered every four or twelve weeks, potentially allowing for only four doses per year, which may represent a significant advancement in treatment options for atopic dermatitis [2][5][10] Study Details - The COAST 1 study was a randomized, double-blind, placebo-controlled trial involving 601 participants aged 12 years and older with moderate-to-severe atopic dermatitis, conducted across 15 countries [9] - Key endpoints included the proportion of patients achieving a validated investigator global assessment scale for AD (vIGA-AD) of 0 or 1 and a reduction from baseline score of ≥2 points, as well as a 75% or greater improvement in the eczema area and severity index total score (EASI-75) [2][3][9] Efficacy Results - At Week 24, 21.1% of patients on Q4W and 22.5% on Q12W achieved vIGA-AD 0/1 compared to 9.2% in the placebo group, with p-values <0.01 [3] - EASI-75 was achieved by 35.9% of patients on Q4W and 39.1% on Q12W, compared to 19.1% in the placebo group, with p-values <0.001 [3] Safety Profile - Amlitelimab was well-tolerated, with no new safety concerns identified; the most common treatment-emergent adverse events were mild and included atopic dermatitis, nasopharyngitis, and upper respiratory tract infection, all more common in the placebo group [7][8] - Injection site reactions were slightly higher in the amlitelimab arms (2.2%) compared to placebo (0.7%), but all were mild and resolved without discontinuation of the study medication [7] Future Outlook - Additional phase 3 results from the OCEANA clinical development program, which includes COAST 1 and four other studies, are expected through 2026 and will inform potential global regulatory submissions [8][10] - Amlitelimab is under clinical investigation and has not yet been evaluated by any regulatory authority [8]

Core Insights - The US FDA has approved Wayrilz (rilzabrutinib) for adults with persistent or chronic immune thrombocytopenia (ITP) who have not responded adequately to previous treatments, based on the successful LUNA 3 phase 3 study [1][3] - Wayrilz is a novel oral Bruton's tyrosine kinase (BTK) inhibitor that targets multiple immune pathways to address the underlying causes of ITP [2][11] - The approval highlights Sanofi's commitment to developing innovative therapies for rare and immunological diseases [3][11] Study Results - The LUNA 3 study involved 202 adult patients and demonstrated that 64% of patients on Wayrilz achieved a platelet count response at 12 weeks compared to 32% in the placebo group [3][10] - Patients on Wayrilz reported a 10.6-point improvement in health-related quality of life measures, while the placebo group showed a 2.3-point increase [4] - Statistically significant results included a durable platelet response at week 25 (23% in Wayrilz vs. 0% in placebo; p<0.0001) and a faster time to first platelet response (36 days in Wayrilz vs. not reached in placebo; p<0.0001) [7] Treatment Implications - Wayrilz offers a new treatment option for patients who have not responded to steroids or existing therapies, potentially improving management of ITP [5][11] - The drug has received Fast Track and Orphan Drug Designations from the FDA for ITP and is under regulatory review in the EU and China [8][12] - Sanofi's HemAssist program will provide support for patients undergoing treatment with Wayrilz, including assistance with access and insurance coverage [9] Company Overview - Sanofi is an R&D driven biopharma company focused on innovative therapies for various diseases, including rare and immunological conditions [13] - The company is committed to leveraging its understanding of the immune system to develop effective treatments and improve patient outcomes [13]